- HIV-1 infection in combination with ≥2 additional antiretroviral agents in documented NNRTI resistance:
- Adults:
- PO 200mg BD
- PO 200mg BD
- Adults:
-
- 2 years to 18 years and >10kg:
- 10-20kg: 100mg BD
- 21-25kg: 125mg BD
- 25-30kg: 150mg BD
- >30kg: 200mg BD
- 2 years to 18 years and >10kg:
- Tablet:
- 25mg
- 100mg
- To be taken after meals
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
It binds directly to reverse transcriptase and blocks RNA and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme’s catalytic sites in HIV 1
- Rash
- Diarrhea in pediatric patients
- Peripheral neuropathy
- Elevated ALT/AST
- Elevated creatine
- Hypercholesterolemia
- Hypertriglyceridemia
- Hyperglycemia
- Lipodystrophy
- Hypersensitivity to class/components
- Breastfeeding
- Artemether/lumefantrine
- Carbamazepine
- Cariprazine
- Cobimetinib
- Doravirine
- Efavirenz
- Elvitegravir/cobicistat/emtricitabine/tenofovir
- Ergonovine
- Fosamprenavir
- Indinavir
- Isavuconazonium
- Lonafarnib
- Lorlatinib
- Lumacaftor/ivacaftor
- Lumefantrine
- Mavacamten
- Naloxegol
- Nelfinavir
- Nevirapine
- Ombitasvir/paritaprevir/ritonavir/dasabuvir
- Pacritinib
- Panobinostat
- Phenobarbital
- Praziquantel
- Regorafenib
- Rifampin
- Rilpivirine
- Roflumilast
- Tipranavir
- Vandetanib
- Velpatasvir
Drug Status
| Availability | Prescription only |
| Pregnancy | Category B |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Intelence | 25mg | Tablet | 120’s | Janssen-Cilag | Phillips Therapeutics |
| Intelence | 100mg | Tablet | 120’s | Janssen-Cilag | Phillips Therapeutics |